Navigation Links
3-Drug Combo Reduces Nausea After Chemo
Date:5/11/2009

Study finds adding casopitant mesylate to regimen cuts side effects

MONDAY, May 11 (HealthDay News) -- The addition of the drug casopitant mesylate (CM) to the conventional two-drug regimen of dexamethasone and ondansetron greatly reduces chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC), a new study concludes.

HEC is used to treat many types of solid tumor cancers, including colorectal and pancreatic cancer. Drugs such as dexamethasone and ondansetron are effective in reducing CINV in the first 24 hours after chemotherapy but only provide moderate relief during the delayed phase (24 to 120 hours after chemotherapy).

The phase 3 study included 810 patients who were receiving dexamethasone and ondansetron after undergoing HEC. They were randomly selected to also receive either a placebo (269 patients), a single 150-milligram oral dose of CM (271), or three-day intravenous plus oral CM (90-mg intravenous on the first day plus 50-mg oral on the second and third days).

The study found that 86 percent of patients in the single oral CM group and 80 percent of those in the intravenous plus oral CM group achieved a complete response (no vomiting, retching or use of rescue medications) for the first 120 hours after their first cycle of HEC treatment, compared with 66 percent of patients in the placebo group.

"A three-drug regimen including a single oral dose or three-day intravenous plus oral regimen of casopitant mesylate plus dexamethasone and ondansetron significantly reduced CINV events in patients receiving HEC compared with a two-drug regimen of dexamethasone and ondansetron," wrote Steven Grunberg, a professor at the University of Vermont, Burlington, and colleagues.

The study appears online and in the June print edition of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about managing chemotherapy-related nausea and vomiting.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, May 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 3-drug combination extremely promising as first-line therapy for multiple myeloma
2. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
3. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
4. Radiation and drug combo helps boost efficacy of lung cancer treatment
5. Aerobic, Weight Training Combo Best Against Diabetes
6. New antibiotic drug combo to speed up treatment of tuberculosis
7. Drug Combo Helps Fight Marfan Syndrome
8. Drug Combo Blocks Pain Without Impairing Movement
9. Two-Drug Combo Fights Brain Tumors
10. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
11. Drug Combo Boosts Multiple Myeloma Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
3-Drug Combo Reduces Nausea After Chemo
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: